MedPath

Enalaprilat

Generic Name
Enalaprilat
Drug Type
Small Molecule
Chemical Formula
C18H24N2O5
CAS Number
76420-72-9
Unique Ingredient Identifier
Q508Q118JM

Overview

Enalaprilat is the active metabolite of the orally available pro-drug, enalapril. Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume. Enalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth. Removal of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril. Enalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible.

Indication

Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical.

Associated Conditions

  • Diabetic Nephropathy
  • Heart Failure
  • Hypertension
  • Left Ventricular Dysfunction

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Hikma Pharmaceuticals USA Inc.
0143-9787
INTRAVENOUS
1.25 mg in 1 mL
1/4/2024
HF Acquisition Co LLC, DBA HealthFirst
51662-1477
INTRAVENOUS
1.25 mg in 1 mL
2/22/2024
Dr. Reddys Laboratories Inc
43598-078
INTRAVENOUS
1.25 mg in 1 mL
4/20/2023
Dr. Reddys Laboratories Inc
43598-169
INTRAVENOUS
2.5 mg in 2 mL
4/20/2023
Hikma Pharmaceuticals USA Inc.
0143-9786
INTRAVENOUS
2.5 mg in 2 mL
1/4/2024

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
KORANDIL 20 TABLET 20MG
SIN14265P
TABLET
20mg
10/30/2012

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
ENALAPRILAT INJECTION USP
hikma canada limited
02388499
Solution - Intravenous
1.25 MG / ML
9/10/2012
VASOTEC IV
01923846
Solution - Intravenous
1.25 MG / ML
12/31/1992

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.